CinnaGen Initiates a Phase 3 Clinical Trial of Vaxine’s COVID-19 Vaccine Technology

  On August 07, 2021, the first volunteer enrolled in the Phase 3 clinical study of Cinnagen’s COVID-19 vaccine candidate in Iran. The study is a randomized, double-blind, placebo-controlled trial and will evaluate the efficacy and safety of the vaccine in 16,876 adult participants. Subjects receive two doses, 21 days apart, of either Spikogen vaccine or […]

Promising clinical trial of Vaxine’s Covid-19 vaccine technology

CinnaGen Co. announced that the results of preliminary analysis of data from the ongoing Phase 2 human clinical trial of spikogen vaccine based on Vaxine’s COVID-19 vaccine technology were positive. This vaccine comprises a recombinant spike protein antigen formulated with the proprietary Advax-SM adjuvant. The Phase 2 study was a randomized, double-blind, placebo-controlled trial conducted on […]

Early Promising Data From the Phase 1 Clinical Trial of the Vaxine’s COVID-19 Vaccine

The Phase 1 trial of COVAX-19®, the Australian COVID-19 vaccine developed by Vaxine Pty Ltd, was independently conducted by the PARC clinical trial team, a University of Adelaide based research group. The study was started on June 30, 2020, at the Royal Adelaide Hospital and included 40 healthy participants aged between 18 and 65 years. […]